Newest drugs

C Diff Infection – Hypervirulent NAP1 Strain and Fidaxomicin

There are multiple strains of C Diff floating around our hospitals and this one is pretty scary.  “This NAP1 strain has a genetic change that results in literally 16 to 23 times more toxin,” says William Jarvis, MD according to an excellent recent College of American Pathologists article [1].  In the same article, L. Clifford […]

Read More

Fidaxomicin (formerly OPT-80, PAR-101 or Difimicin)

It looks like “Fidaxomicin (formerly OPT-80, PAR-101 or Difimicin),” is still looking very promising so be sure to keep searching for its new name, Fidaxomicin. [1]  Again, Fidaxomicin is a new drug soon to complete its last studies before applying for FDA approval.  It has been shown, so far, to a tiny bit more effective […]

Read More

Opt-80 Higher Cure and Lower Relapse Rates

According to TheStreet.com [1], top-line results of Optimer’s phase III Opt-80 study are demonstrating higher cure rates and lower relapse rates when compared to vancomycin. Cure Rates Similar If you ask me, the cure rates were similar (88% versus 86%), but this is still fantastic news.  Currently, there are two antibiotics being widely used to […]

Read More

OPT-80 Clinical Trials Have Begun

This drug is looking promising to me and it is getting much closer to being available.  The FDA has granted this drug Fast-Track status.  According to a great pdf from the maker of the drug, the company estimates that its second (and I think final) trial will complete in 2009.[1] After that the FDA/EAMA begin […]

Read More

A New C Diff Antibiotic

OPT-80 (or “PAR-101” or “Difimicin”) According to PipelineReview.com and Optimer Pharmaceuticals, there may be a new drug coming out that  “may eradicate C. difficile selectively,” [1] which could be a huge breakthrough in the treatment of Clostridium Difficile infections. This drug is fantastic news for people suffering from multiple relapses. The makers of the new […]

Read More